35 related articles for article (PubMed ID: 38464081)
1. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J; Chen Z; Qiao Y; Tien JC; Young E; Mannan R; Mahapatra S; He T; Eyunni S; Zhang Y; Zheng Y; Su F; Cao X; Wang R; Cheng Y; Seri R; George J; Shahine M; Miner SJ; Vaishampayan U; Wang M; Wang S; Parolia A; Chinnaiyan AM
bioRxiv; 2024 May; ():. PubMed ID: 38586029
[TBL] [Abstract][Full Text] [Related]
2. Publisher Correction: PU.1 and BCL11B sequentially cooperate with RUNX1 to anchor mSWI/SNF to poise the T cell effector landscape.
Gamble N; Bradu A; Caldwell JA; McKeever J; Bolonduro O; Ermis E; Kaiser C; Kim Y; Parks B; Klemm S; Greenleaf WJ; Crabtree GR; Koh AS
Nat Immunol; 2024 Jun; 25(6):1123. PubMed ID: 38755325
[No Abstract] [Full Text] [Related]
3. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
He T; Xiao L; Qiao Y; Klingbeil O; Young E; Wu XS; Mannan R; Mahapatra S; Eyunni S; Ching-Yi Tien J; Wang X; Zheng Y; Kim N; Zheng H; Hou S; Su F; Miner SJ; Mehra R; Cao X; Abbineni C; Samajdar S; Ramachandra M; Parolia A; Vakoc CR; Chinnaiyan AM
bioRxiv; 2024 May; ():. PubMed ID: 38328238
[TBL] [Abstract][Full Text] [Related]
5. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.
Xiao L; Parolia A; Qiao Y; Bawa P; Eyunni S; Mannan R; Carson SE; Chang Y; Wang X; Zhang Y; Vo JN; Kregel S; Simko SA; Delekta AD; Jaber M; Zheng H; Apel IJ; McMurry L; Su F; Wang R; Zelenka-Wang S; Sasmal S; Khare L; Mukherjee S; Abbineni C; Aithal K; Bhakta MS; Ghurye J; Cao X; Navone NM; Nesvizhskii AI; Mehra R; Vaishampayan U; Blanchette M; Wang Y; Samajdar S; Ramachandra M; Chinnaiyan AM
Nature; 2022 Jan; 601(7893):434-439. PubMed ID: 34937944
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.
Wei J; Patil A; Collings CK; Alfajaro MM; Liang Y; Cai WL; Strine MS; Filler RB; DeWeirdt PC; Hanna RE; Menasche BL; Ökten A; Peña-Hernández MA; Klein J; McNamara A; Rosales R; McGovern BL; Luis Rodriguez M; García-Sastre A; White KM; Qin Y; Doench JG; Yan Q; Iwasaki A; Zwaka TP; Qi J; Kadoch C; Wilen CB
Nat Genet; 2023 Mar; 55(3):471-483. PubMed ID: 36894709
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
8. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464081
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
10. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
Chabanon RM; Morel D; Postel-Vinay S
Semin Cancer Biol; 2020 Apr; 61():180-198. PubMed ID: 31568814
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
